These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28786131)

  • 1. Links between causal effects and causal association for surrogacy evaluation in a gaussian setting.
    Conlon A; Taylor J; Li Y; Diaz-Ordaz K; Elliott M
    Stat Med; 2017 Nov; 36(27):4243-4265. PubMed ID: 28786131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
    Taylor JM; Conlon AS; Elliott MR
    Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogacy assessment using principal stratification and a Gaussian copula model.
    Conlon A; Taylor J; Elliott MR
    Stat Methods Med Res; 2017 Feb; 26(1):88-107. PubMed ID: 24947559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
    Conlon AS; Taylor JM; Elliott MR
    Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accommodating missingness when assessing surrogacy via principal stratification.
    Elliott MR; Li Y; Taylor JM
    Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solutions for surrogacy validation with longitudinal outcomes for a gene therapy.
    Roberts EK; Elliott MR; Taylor JMG
    Biometrics; 2023 Sep; 79(3):1840-1852. PubMed ID: 35833874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A reflection on the causal interpretation of individual-level surrogacy.
    Alonso A; Van Der Elst W; Molenberghs G; Florez AJ
    J Biopharm Stat; 2019; 29(3):529-540. PubMed ID: 30773114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive cluster level surrogacy in the presence of interference.
    Gabriel EE; Follmann DA
    Biostatistics; 2020 Apr; 21(2):e33-e46. PubMed ID: 30247535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Related causal frameworks for surrogate outcomes.
    Joffe MM; Greene T
    Biometrics; 2009 Jun; 65(2):530-8. PubMed ID: 18759836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference.
    Alonso A; Van der Elst W; Molenberghs G; Buyse M; Burzykowski T
    Biometrics; 2016 Sep; 72(3):669-77. PubMed ID: 26864244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm.
    Roberts EK; Elliott MR; Taylor JMG
    Stat Med; 2021 Dec; 40(29):6605-6618. PubMed ID: 34528260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogacy marker paradox measures in meta-analytic settings.
    Elliott MR; Conlon AS; Li Y; Kaciroti N; Taylor JM
    Biostatistics; 2015 Apr; 16(2):400-12. PubMed ID: 25236906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing a surrogate predictive value: a causal inference approach.
    Alonso A; Van der Elst W; Meyvisch P
    Stat Med; 2017 Mar; 36(7):1083-1098. PubMed ID: 27966231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bayesian approach to surrogacy assessment using principal stratification in clinical trials.
    Li Y; Taylor JM; Elliott MR
    Biometrics; 2010 Jun; 66(2):523-31. PubMed ID: 19673864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data.
    Chen H; Geng Z; Zhou XH
    Biometrics; 2009 Sep; 65(3):675-82. PubMed ID: 18759847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The individual-level surrogate threshold effect in a causal-inference setting with normally distributed endpoints.
    Van der Elst W; Abad AA; Coppenolle H; Meyvisch P; Molenberghs G
    Pharm Stat; 2021 Nov; 20(6):1216-1231. PubMed ID: 34018666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.
    Gilbert PB; Hudgens MG; Wolfson J
    Int J Biostat; 2011; 7(1):Article 36. PubMed ID: 22049267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principal stratification--a goal or a tool?
    Pearl J
    Int J Biostat; 2011 Mar; 7(1):20. PubMed ID: 21556288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and validation of social and psychological markers in randomised trials of complex interventions in mental health: a methodological research programme.
    Dunn G; Emsley R; Liu H; Landau S; Green J; White I; Pickles A
    Health Technol Assess; 2015 Nov; 19(93):1-115, v-vi. PubMed ID: 26560448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.